The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Diagnosing, Treating IgG4-Related Disease

Diagnosing, Treating IgG4-Related Disease

September 15, 2015 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“The goal of creating this International Consensus Guidelines Statement was to capture the expertise of clinicians and clinical investigators from across the world with extensive experience in the management and treatment of IgG4,” says Dr. Khosroshahi, adding that the guidelines are intended to help inform clinical management of this disease worldwide until better cohort and prospective studies are conducted.

You Might Also Like
  • International Consensus Statement on the Management & Treatment of IgG4-Related Disease
  • Resarch Into IgG4-Related Diseases Expands Knowledge Base, Leads to Effective Treatments
  • Draft Classification Criteria for IgG4-Related Disease Introduced
Explore This Issue
September 2015
Also By This Author
  • Institute for Clinical Economic Review Final Report on RA Treatments

Takeaway for Rheumatologists

One key message highlighted by the findings of the consensus statement is the importance of accurate and early diagnosis to ensure optimal management of the disease that can affect many organs.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The senior author of the study, John H. Stone, MD, MPH, professor of medicine, Harvard Medical School, director of clinical rheumatology, Massachusetts General Hospital, Boston, emphasized that the guidance statement indicates for the first time that experts agree on a low threshold for initiating treatment in patients with active disease. As shown in Table 1, recommendation No. 3, 87% of experts agreed on the importance of early treatment.

“Although IgG4-related disease generally has a subacute presentation, irreversible injury to some organs can occur within weeks or months if effective therapy is not initiated,” he says, emphasizing that a major goal of therapy identified by the experts is the prevention of fibrosis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Once fibrosis is established, therapeutic options are currently limited,” Dr. Stone says.

Clinical manifestations that require urgent therapy, he says, include aortitis, retroperitoneal fibrosis, proximal biliary strictures, tubulointerstitial nephritis, pachymeningitis, type 1 autoimmune pancreatitis and pericarditis.

Commenting on the consensus statement, Eric Matteson, MD, chair of the Division of Rheumatology, Mayo Clinic, Rochester, Minn., highlighted the help offered by the consensus statement in underscoring the numerous conditions associated with IgG4-related disease, as well as the conditions that mimic this disease.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One key message … is the importance of accurate & early diagnosis to ensure optimal management of the disease that can affect many organs …. [I]rreversible injury to some organs can occur within weeks or months if effective therapy is not initiated.

He also stresses the importance of prompt treatment. “The guidelines help emphasize the need for recognition of, and prompt and aggressive treatment of the disease, which substantially limit the organ damage and comorbidities associated with it,” he says.

To help make the diagnosis, Dr. Stone emphasizes the need for close collaboration between clinicians and pathologists because neither clinical nor pathologic findings alone are sufficient for diagnosis in most cases.

“I find it enormously helpful to sit at the microscope with the pathologist and review biopsy slides myself,” he says, adding that the collaboration is equally beneficial to the pathologist and generates a “remarkable synergy.”

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: Clinical, Diagnosis, IgG4 related disease, outcome, patient care, TreatmentIssue: September 2015

You Might Also Like:
  • International Consensus Statement on the Management & Treatment of IgG4-Related Disease
  • Resarch Into IgG4-Related Diseases Expands Knowledge Base, Leads to Effective Treatments
  • Draft Classification Criteria for IgG4-Related Disease Introduced
  • Gene Signatures in IgG4-Related Disease

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.